Skip to main content
. 2022 Aug 9;41(2):154–162. doi: 10.2337/cd22-0016

TABLE 2.

Approved Biosimilar Insulins (3033)

Reference Products Biosimilars (Year Approved) Action
Insulin glargine Basaglar*/Abasaglar (2015/2014)
Lusduna (2017)
Semglee (2020)
Long-acting
Insulin lispro Admelog* (2017) Short-acting
Insulin aspart Insulin aspart Sanofi (2020)
Sar-Asp (2020)
Kixelle (2021)
*

Products approved in the United States before 23 March 2020 were termed “follow-on biologics.”

Approved in the European Union.